EGETIS THERAPEUTICS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.75 SEK | -3.20% |
|
-9.73% | +3.05% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Egetis Therapeutics AB (publ), formerly PledPharma AB (publ) is a Sweden-based pharmaceutical drug development company, focusing on projects in late-stage development for treatment of diseases with unmet medical needs in the orphan drug segment. The Companyâs pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.
Calendar
2024-05-02
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
5.75
SEK
Average target price
13.12
SEK
Spread / Average Target
+128.26%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.05% | 153M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- EGTX Stock
- News Egetis Therapeutics AB
- Egetis Therapeutics Grants Fujimoto Pharmaceutical Exclusive Rights to Emcitate in Japan; Stock Rises
